<DOC>
	<DOCNO>NCT00003190</DOCNO>
	<brief_summary>Randomized phase III trial compare effectiveness combination chemotherapy without PSC 833 follow interleukin-2 therapy treat old patient acute myeloid leukemia . Some cancer become resistant chemotherapy drug . Combining PSC 833 one chemotherapy drug may reduce resistance drug allow cancer cell kill . Combining interleukin-2 combination chemotherapy plus PSC 833 may kill cancer cell .</brief_summary>
	<brief_title>Combination Chemotherapy With Without Valspodar Treating Patients With Previously Untreated Acute Myeloid Leukemia</brief_title>
	<detailed_description>PRIMARY OBJECTIVES : I . To determine whether addition PSC-833 induction chemotherapy improve complete response rate whether addition PSC-833 induction consolidation chemotherapy improve survival patient AML &gt; = 60 year . II . To determine whether administration low-dose , subcutaneous rIL-2 immunotherapy intermittent high-dose bolus chemotherapy prolongs disease-free survival . OUTLINE : This partially randomize , multicenter study . Patients stratify accord participate center disease characteristic ( de novo acute myeloid leukemia ( AML ) versus AML antecedent myelodysplasia ) . Patients randomize one two maintenance therapy arm . Arm I : Patients receive cytarabine IV continuously 7 day daunorubicin IV bolus follow etoposide IV 2 hour day 1-3 . Arm II : Patients receive treatment arm I addition PSC 833 induction . A load dose PSC 833 IV give 2 hour , follow 74-hour continuous infusion PSC 833 begin 2 hour daunorubicin etoposide . Patients may receive second induction course residual leukemia present bone marrow . Patients experience complete remission ( CR ) meet certain criterion receive postremission chemotherapy consist cytarabine IV continuously 5 day plus daunorubicin IV follow etoposide IV 2 hour day 1 2 . Patients randomize receive PSC 833 induction chemotherapy receive load dose PSC 833 begin 48-hour continuous infusion PSC 833 concurrently cytarabine/daunorubicin/etoposide postremission chemotherapy . After complete postremission chemotherapy , patient randomize treatment group interleukin-2 ( IL-2 ) immunotherapy . Treatment begin within 5 month postremission chemotherapy . IL-2 immunotherapy consist low-dose subcutaneous ( SC ) IL-2 day 1-14 , 19-28 , 33-42 , 47-56 , 61-70 , 75-90 high-dose bolus SC IL-2 day 15-17 , 29-31 , 43-45 , 57-59 , 71-73 . Patients follow every 2 month 2 year , every 6 month 2 year , annually tenth year , relapse .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Leukemia , Monocytic , Acute</mesh_term>
	<mesh_term>Leukemia , Myelomonocytic , Acute</mesh_term>
	<mesh_term>Leukemia , Erythroblastic , Acute</mesh_term>
	<mesh_term>Leukemia , Megakaryoblastic , Acute</mesh_term>
	<mesh_term>Etoposide</mesh_term>
	<mesh_term>Daunorubicin</mesh_term>
	<mesh_term>Etoposide phosphate</mesh_term>
	<mesh_term>Cytarabine</mesh_term>
	<mesh_term>Cyclosporins</mesh_term>
	<criteria>Unequivocal histologic diagnosis AML , FAB classification ( M0M7 ) , exclude M3 ( acute promyelocytic leukemia ) ; patient history antecedent myelodysplasia remain eligible treatment trial No prior treatment acute leukemia myelodysplasia four permissible exception : Emergency leukapheresis ; Emergency treatment hyperleukocytosis hyroxyurea ; Cranial RT CNS leukostasis ( one dose ) ; Growth factor/cytokine support .</criteria>
	<gender>All</gender>
	<minimum_age>60 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2013</verification_date>
</DOC>